Novo Nordisk A/S (NNO2.VI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Lars Fruergaard Jorgensen | President, CEO & Member of Management Board | 4.33M | -- | 1966 |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 1.72M | -- | 1971 |
| Mr. Henrik Ehlers Wulff | Executive VP of CMC & Product Supply and Member of the Management Board | 1.73M | -- | 1970 |
| Dr. Martin Holst Lange | Executive VP of Development & Member of the Management Board | 1.64M | -- | 1970 |
| Dr. Marcus Schindler Ph.D. | EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board | 1.64M | -- | 1966 |
| Mr. Maziar Mike Doustdar | Executive VP of International Operations & Member of the Management Board | -- | -- | 1970 |
| Mr. Ludovic Helfgott | Executive VP of Product & Portfolio Strategy and Member of Management Board | -- | -- | 1974 |
| Ms. Tania Sabroe | EVP of People, Organisation and Communication & Member of Management Board | -- | -- | 1977 |
| Mr. David S. Moore | Executive VP of US Operations & Member of Management Board | -- | -- | 1974 |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Quality, IT & Environmental Affairs and Member of Management Board | -- | -- | -- |
Novo Nordisk A/S
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 77,406
Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Corporate Governance
Upcoming Events
August 6, 2025 at 5:30 AM UTC
Novo Nordisk A/S Earnings Date
Recent Events
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date
August 23, 1970 at 12:00 AM UTC
Dividend Date